• For Individuals
  • For Institutions
  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
LB Café
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec5
Stoke Therapeutics and Biogen Show Positive Data for Dravet Syndrome Drug
14:00
Dec1
Stoke Therapeutics and Biogen to Present New Clinical Data on Zorevunersen at AES Annual Meeting
12:30
Nov7
HC Wainwright Cuts Stoke Therapeutics 2029 EPS Forecast
14:26
Nov5
Stoke Therapeutics to Speak on Zorevunersen at Guggenheim Healthcare Innovation Conference
21:02
Stoke Therapeutics released FY2025 9 Months earnings on November 4 After-Market (EST), actual revenue USD 183.02 M, actual EPS USD 0.8433
00:00
Stoke Therapeutics released FY2025 Q3 earnings on November 4 After-Market EST, actual revenue USD 10.63 M (forecast USD 6.16 M), actual EPS USD -0.6542 (forecast USD -0.577)
00:00

Schedules & Filings

Schedules
Filings
Nov4
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 10.63 M, Net Income -38.35 M, EPS -0.6542

Aug12
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 13.82 M, Net Income -23.48 M, EPS -0.4024

May13
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 158.57 M, Net Income 112.88 M, EPS 1.9

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
GURE
9.400
+98.31%
+4.660
WHLR
6.210
+91.67%
+2.929
SMX
232.365
+64.80%
+95.130
IRBT
4.565
+50.66%
+1.518
PAVS
0.0465
+47.62%
+0.015
TDIC
0.4026
+43.38%
+0.122
PRAX
264.915
+39.45%
+75.360
TGL
9.270
+37.17%
+2.512
TORO
5.570
+34.86%
+1.390
AKAN
1.200
+26.85%
+0.255
View More